Relapsed and Refractory Multiple Myeloma Treatment Market By Treatment Type (Chemotherapy, Radiotherapy, Stem Cell Transplantation, Others), By Drug Class (Monoclonal Antibodies, Immunomodulatory Drugs, Proteasome Inhibitors, Steroids, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospitals, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Relapsed and refracted multiple myeloma market is poised to grow at a significant CAGR owing to increase in the prevalence of multiple myeloma. According to World Cancer Research Fund International 2012, approximately 114,000 multiple myeloma cases observed around the world. According to Novartis data 2015, approximately 75,000 people are living with relapsed and refractory multiple myeloma around the globe. Moreover, strong product pipeline for relapsed and refractory multiple myeloma treatment expected to boost the market. For instance, in April 2017, Genmab A/S announced that Janssen Research and Development LLC collaborated with European Myeloma Network (EMN) to start phase III study of daratumumab in combination with dexamethasone and pomalidomide in relapsed and refractory multiple myeloma. In addition, FDA approval for various drugs might upsurge the revenue of market. For instance, in January 2016, Amgen received FDA approval for supplemental New Drug Application (sNDA) of Kyprolis (carfilzomib) injection in combination with lenalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma. Relapsed multiple myeloma occurs when the multiple myeloma disease or its signs and symptoms return after a period of improvement. Relapsed and Refractory Multiple Myeloma Treatment Market occurs when the disease in unresponsive to a primary therapy or it becomes unresponsive over time. Multiple myeloma or plasma cell myeloma, is a cancer of plasma cells, a type of WBC normally responsible for the production of antibodies. At initial stage, there are no symptoms noticed with multiple myeloma, however, in advanced stage bleeding, bone pain, anemia, and frequent infections may occur. Risk factors for multiple myeloma are high consumption of alcohol and obesity. It may causes due to abnormal production of antibodies may cause renal problems and increase in the thickness of blood. The disease can be considered as treatable, but incurable. It can be treated with radiotherapy, chemotherapy, and stem cell transplantation among others.

Relapsed And Refractory Multiple Myeloma Treatment Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Relapsed And Refractory Multiple Myeloma Treatment Market Dynamics

Increase in the prevalence of relapsed and refractory multiple myeloma, rise in R&D for the innovation of newer drugs, funding for the R&D activities from public and private sectors, and promising pipeline products are anticipated to fuel the relapsed and refractory multiple myeloma treatment market over the forecast years. Moreover, increase in awareness about relapsed and refractory myeloma treatment, government initiations for prevention of cancer, and launching of newer products into the market are bolster the relapsed and refractory multiple myeloma treatment market. However, stringent regulatory policies for product approval, high cost of R&D activities, and adverse effects associated with chemotherapy and radiotherapy may hinder the growth of the market over the forecast timeframe.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Relapsed And Refractory Multiple Myeloma Treatment Market Segmentation

Treatment Type
  • Chemotherapy
  • Radiotherapy
  • Stem Cell Transplantation
  • Others
Drug Class
  • Monoclonal Antibodies
  • Immunomodulatory Drugs
  • Proteasome Inhibitors
  • Steroids
  • Others
  • Oral
  • Parenteral
Distribution Channel
  • Hospitals
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


[urltag url='request-table-of-content']

  • GlaxoSmithKline plc (U.K.)
  • AstraZeneca plc (U.K.)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GenMab A/S (Denmark)
  • Amgen Inc. (U.S.)
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) (U.S.)
  • Unum Therapeutics (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Celgene Corporation (U.S.)
  • Bluebird Bio, Inc. (U.S.)